{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:06:08Z","timestamp":1793066768391,"version":"4.5.0"},"publisher-location":"New York, NY","reference-count":75,"publisher":"Springer US","isbn-type":[{"value":"9781493998449","type":"print"},{"value":"9781493998456","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:00:00Z","timestamp":1569974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-1-4939-9845-6_10","type":"book-chapter","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T22:04:07Z","timestamp":1569967447000},"page":"185-204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Methods for Evaluation of a Snake Venom-Derived Disintegrin in Animal Models of Human Cancer"],"prefix":"10.1007","author":[{"given":"Stephen D.","family":"Swenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Silva-Hirschberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis S.","family":"Markland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,2]]},"reference":[{"issue":"3","key":"10_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1161\/ATVBAHA.107.150474","volume":"28","author":"D Varga-Szabo","year":"2008","unstructured":"Varga-Szabo D, Pleines I, Nieswandt B (2008) Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 28(3):403\u2013412","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3181\/00379727-195-43129B","volume":"195","author":"RJ Gould","year":"1990","unstructured":"Gould RJ, Polokoff MA, Friedman PA et al (1990) Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc Soc Exptl Biol Med 195(2):168\u2013171","journal-title":"Proc Soc Exptl Biol Med"},{"issue":"28","key":"10_CR3","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.2174\/138161207782023793","volume":"13","author":"S Swenson","year":"2007","unstructured":"Swenson S, Ramu S, Markland FS (2007) Anti-angiogenesis and RGD-containing snake venom disintegrins. Curr Pharm Des 13(28):2860\u20132871","journal-title":"Curr Pharm Des"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"6617","DOI":"10.2741\/3177","volume":"13","author":"MA McLane","year":"2008","unstructured":"McLane MA, Joerger T, Mahmoud A (2008) Disintegrins in health and disease. Front Biosci 13:6617\u20136637","journal-title":"Front Biosci"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"7369","DOI":"10.1021\/bi00244a003","volume":"30","author":"V Saudek","year":"1991","unstructured":"Saudek V, Atkinson RA, Pelton JT (1991) Three-dimensional structure of echistatin, the smallest active RGD protein. Biochemistry 30:7369\u20137372","journal-title":"Biochemistry"},{"issue":"Pt 4","key":"10_CR6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1107\/S0907444908002370","volume":"64","author":"N Moiseeva","year":"2008","unstructured":"Moiseeva N, Bau R, Swenson SD et al (2008) Structure of acostatin, a dimeric disintegrin from Southern copperhead (Agkistrodon contortrix contortrix), at 1.7 A resolution. Acta Crystallogr D Biol Crystallogr 64(Pt 4):466\u2013470","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 2","key":"10_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1242\/jcs.018556","volume":"122","author":"JA Askari","year":"2009","unstructured":"Askari JA, Buckley PA, Mould AP et al (2009) Linking integrin conformation to function. J Cell Sci 122(Pt 2):165\u2013170","journal-title":"J Cell Sci"},{"issue":"36","key":"10_CR8","doi-asserted-by":"crossref","first-page":"21550","DOI":"10.1016\/S0021-9258(20)88220-9","volume":"264","author":"RJ Shebuski","year":"1989","unstructured":"Shebuski RJ, Ramjit DR, Bencen GH et al (1989) Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans. J Biol Chem 264(36):21550\u201321556","journal-title":"J Biol Chem"},{"issue":"3","key":"10_CR9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1161\/01.CIR.83.3.1038","volume":"83","author":"T Yasuda","year":"1991","unstructured":"Yasuda T, Gold HK, Leinbach RC et al (1991) Kistrin, a polypeptide platelet GPIIb\/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation 83(3):1038\u20131047","journal-title":"Circulation"},{"key":"10_CR10","first-page":"A938","volume":"9","author":"GR Cousins","year":"1995","unstructured":"Cousins GR, Sudo Y, Friedrichs GR et al (1995) Contortrostatin prevents reocclusion after thrombolytic therapy in a canine model of carotid artery thrombosis. FASEB J 9:A938","journal-title":"FASEB J"},{"issue":"6","key":"10_CR11","doi-asserted-by":"publisher","first-page":"e10929","DOI":"10.1371\/journal.pone.0010929","volume":"5","author":"RO Minea","year":"2010","unstructured":"Minea RO, Helchowski CM, Zidovetzki SJ et al (2010) Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities. PLoS One 5(6):e10929","journal-title":"PLoS One"},{"issue":"4","key":"10_CR12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.toxicon.2011.02.020","volume":"59","author":"R Minea","year":"2012","unstructured":"Minea R, Helchowski C, Rubino B et al (2012) Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential. Toxicon 59(4):472\u2013486","journal-title":"Toxicon"},{"issue":"1","key":"10_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/jcb.10665","volume":"91","author":"JK Slack-Davis","year":"2004","unstructured":"Slack-Davis JK, Parsons JT (2004) Emerging views of integrin signaling: implications for prostate cancer. J Cell Biochem 91(1):41\u201346","journal-title":"J Cell Biochem"},{"issue":"1","key":"10_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0092-8674(92)90115-S","volume":"69","author":"RO Hynes","year":"1992","unstructured":"Hynes RO (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69(1):11\u201325","journal-title":"Cell"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/0046-8177(92)90034-Z","volume":"23","author":"M Pignatelli","year":"1992","unstructured":"Pignatelli M, Cardillo MR, Hanby A et al (1992) Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol 23:1159\u20131166","journal-title":"Hum Pathol"},{"issue":"1","key":"10_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI114957","volume":"87","author":"E Ruoslahti","year":"1991","unstructured":"Ruoslahti E (1991) Integrins. J Clin Invest 87(1):1\u20135","journal-title":"J Clin Invest"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0272-2712(18)30514-6","volume":"12","author":"DA Cheresh","year":"1992","unstructured":"Cheresh DA (1992) Structural and biologic properties of integrin-mediated cell adhesion. Clin Lab Med 12:217\u2013236","journal-title":"Clin Lab Med"},{"issue":"3","key":"10_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/sj.neo.7900224","volume":"4","author":"CR Cooper","year":"2002","unstructured":"Cooper CR, Chay CH, Pienta KJ (2002) The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 4(3):191\u2013194","journal-title":"Neoplasia"},{"issue":"3","key":"10_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1677\/ERC-08-0019","volume":"15","author":"HL Goel","year":"2008","unstructured":"Goel HL, Li J, Kogan S et al (2008) Integrins in prostate cancer progression. Endocr Relat Cancer 15(3):657\u2013664","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2174\/1568009614666140403123452","volume":"14","author":"I Israel","year":"2014","unstructured":"Israel I, Richter D, Stritzker J et al (2014) PET imaging with [(6)(8)Ga]NOTA-RGD for prostate cancer: a comparative study with [(1)(8)F]fluorodeoxyglucose and [(1)(8)F]fluoroethylcholine. Curr Cancer Drug Targets 14(4):371\u2013379","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"10_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1389450033346830","volume":"4","author":"CC Kumar","year":"2003","unstructured":"Kumar CC (2003) Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4(2):123\u2013131","journal-title":"Curr Drug Targets"},{"issue":"1","key":"10_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.critrevonc.2015.05.018","volume":"96","author":"S Stucci","year":"2015","unstructured":"Stucci S, Tucci M, Passarelli A et al (2015) Avbeta3 integrin: Pathogenetic role in osteotropic tumors. Crit Rev Oncol Hematol 96(1):183\u2013193","journal-title":"Crit Rev Oncol Hematol"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/cancers9070084","volume":"9","author":"KA Kwakwa","year":"2017","unstructured":"Kwakwa KA, Sterling JA (2017) Integrin alphavbeta3 Signaling in Tumor-Induced Bone Disease. Cancers 9:7","journal-title":"Cancers"},{"key":"10_CR24","doi-asserted-by":"crossref","unstructured":"Juan-Rivera MC, Martinez-Ferrer M (2018) Integrin Inhibitors in Prostate Cancer. Cancers 10(2):PMC5836076","DOI":"10.3390\/cancers10020044"},{"issue":"15","key":"10_CR25","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.1021\/jm5000547","volume":"57","author":"HM Sheldrake","year":"2014","unstructured":"Sheldrake HM, Patterson LH (2014) Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists. J Med Chem 57(15):6301\u20136315","journal-title":"J Med Chem"},{"issue":"12","key":"10_CR26","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/pros.21173","volume":"70","author":"E Lin","year":"2010","unstructured":"Lin E, Wang Q, Swenson S et al (2010) The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. Prostate 70(12):1359\u20131370","journal-title":"Prostate"},{"key":"10_CR27","unstructured":"Markland FS, Swenson S, Minea R (2016) A novel, non-cytotoxic, anti-invasive therapeutic agent for ovarian cancer. In: Proceedings of the 2016 International Conference on Biomedical and Biological Engineering [BBE2016]. Atlantis Press, pp 159\u2013165"},{"issue":"3","key":"10_CR28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3171\/jns.2005.103.3.0526","volume":"103","author":"P Pyrko","year":"2005","unstructured":"Pyrko P, Wang W, Markland FS et al (2005) The role of contortrostatin, a snake venom disintegrin, in the inhibition of tumor progression and prolongation of survival in a rodent glioma model. J Neurosurg 103(3):526\u2013537","journal-title":"J Neurosurg"},{"issue":"1","key":"10_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/stem.5530120107","volume":"12","author":"GA Curt","year":"1994","unstructured":"Curt GA (1994) The use of animal models in cancer drug discovery and development. Stem Cells 12(1):23\u201329","journal-title":"Stem Cells"},{"issue":"1","key":"10_CR30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bcp.2013.06.020","volume":"87","author":"BA Ruggeri","year":"2014","unstructured":"Ruggeri BA, Camp F, Miknyoczki S (2014) Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol 87(1):150\u2013161","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10_CR31","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1023\/A:1006326203858","volume":"17","author":"RM Hoffman","year":"1999","unstructured":"Hoffman RM (1999) Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Investig New Drugs 17(4):343\u2013359","journal-title":"Investig New Drugs"},{"issue":"1","key":"10_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","volume":"163","author":"CP Day","year":"2015","unstructured":"Day CP, Merlino G, Van Dyke T (2015) Preclinical mouse cancer models: a maze of opportunities and challenges. Cell 163(1):39\u201353","journal-title":"Cell"},{"issue":"1","key":"10_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer Statistics, 2019. CA Cancer J Clin 69(1):7\u201334","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10_CR34","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/ijc.24188","volume":"124","author":"KL Sodek","year":"2009","unstructured":"Sodek KL, Ringuette MJ, Brown TJ (2009) Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer 124(9):2060\u20132070","journal-title":"Int J Cancer"},{"issue":"3","key":"10_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1615\/CritRevOncog.v13.i3.10","volume":"13","author":"B Davidson","year":"2007","unstructured":"Davidson B (2007) Biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog 13(3):189\u2013227","journal-title":"Crit Rev Oncog"},{"key":"10_CR36","first-page":"CD005340","volume":"11","author":"K Jaaback","year":"2011","unstructured":"Jaaback K, Johnson N, Lawrie TA (2011) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 11:CD005340","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10_CR37","first-page":"2803","volume":"29","author":"AG Zeimet","year":"2009","unstructured":"Zeimet AG, Reimer D, Radl AC et al (2009) Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer Res 29(7):2803\u20132808","journal-title":"Anticancer Res"},{"issue":"1","key":"10_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34\u201343","journal-title":"N Engl J Med"},{"issue":"4","key":"10_CR39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1634\/theoncologist.2007-0224","volume":"13","author":"I Vergote","year":"2008","unstructured":"Vergote I, Amant F, Leunen K et al (2008) Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view. Oncologist 13(4):410\u2013414","journal-title":"Oncologist"},{"issue":"2","key":"10_CR40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3747\/co.v18i2.725","volume":"18","author":"HJ Mackay","year":"2011","unstructured":"Mackay HJ, Provencheur D, Heywood M et al (2011) Phase ii\/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21. Curr Oncol 18(2):84\u201390","journal-title":"Curr Oncol"},{"issue":"1","key":"10_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","volume":"100","author":"JL Walker","year":"2006","unstructured":"Walker JL, Armstrong DK, Huang HQ et al (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100(1):27\u201332","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10_CR42","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1200\/JCO.2005.05.2456","volume":"24","author":"M Markman","year":"2006","unstructured":"Markman M, Walker JL (2006) Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 24(6):988\u2013994","journal-title":"J Clin Oncol"},{"key":"10_CR43","doi-asserted-by":"crossref","unstructured":"Wright AA, Cronin A, Milne DE et al (2015) Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol 33(26):2841-2847","DOI":"10.1200\/JCO.2015.61.4776"},{"key":"10_CR44","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S0076-6879(05)99035-6","volume":"399","author":"S Gross","year":"2005","unstructured":"Gross S, Piwnica-Worms D (2005) Monitoring proteasome activity in cellulo and in living animals by bioluminescent imaging: technical considerations for design and use of genetically encoded reporters. Methods Enzymol 399:512\u2013530","journal-title":"Methods Enzymol"},{"issue":"11","key":"10_CR45","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1158\/0008-5472.CAN-08-2974","volume":"69","author":"C Gourley","year":"2009","unstructured":"Gourley C, Paige AJ, Taylor KJ et al (2009) WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res 69(11):4835\u20134842","journal-title":"Cancer Res"},{"issue":"3","key":"10_CR46","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1158\/1078-0432.CCR-13-1271","volume":"20","author":"YA Park","year":"2014","unstructured":"Park YA, Lee JW, Kim HS et al (2014) Tumor suppressive effects of bromodomain-containing protein 7 (BRD7) in epithelial ovarian carcinoma. Clin Cancer Res 20(3):565\u2013575","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10_CR47","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1158\/1535-7163.MCT-14-0077","volume":"13","author":"W Wen","year":"2014","unstructured":"Wen W, Liang W, Wu J et al (2014) Targeting JAK1\/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther 13(12):3037\u20133048","journal-title":"Mol Cancer Ther"},{"key":"10_CR48","doi-asserted-by":"crossref","unstructured":"Bilandzic M, Stenvers KL (2014) Assessment of ovarian cancer spheroid attachment and invasion of mesothelial cells in real time. J Vis Exp (87), e51655","DOI":"10.3791\/51655"},{"issue":"7","key":"10_CR49","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00381-008-0771-9","volume":"25","author":"Z Kaderali","year":"2009","unstructured":"Kaderali Z, Lamberti-Pasculli M, Rutka JT (2009) The changing epidemiology of paediatric brain tumours: a review from the Hospital for Sick Children. Childs Nerv Syst 25(7):787\u2013793","journal-title":"Childs Nerv Syst"},{"issue":"3","key":"10_CR50","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00381-005-1178-5","volume":"22","author":"I Prada De","year":"2006","unstructured":"De Prada I, Cordobes F, Azorin D et al (2006) Pediatric giant cell glioblastoma: a case report and review of the literature. Childs Nerv Syst 22(3):285\u2013289","journal-title":"Childs Nerv Syst"},{"issue":"4","key":"10_CR51","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1188\/04.CJON.368-376","volume":"8","author":"S Remer","year":"2004","unstructured":"Remer S, Murphy ME (2004) The challenges of long-term treatment outcomes in adults with malignant gliomas. Clin J Oncol Nurs 8(4):368\u2013376","journal-title":"Clin J Oncol Nurs"},{"issue":"13","key":"10_CR52","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-06-0266","volume":"12","author":"AJ Beer","year":"2006","unstructured":"Beer AJ, Haubner R, Sarbia M et al (2006) Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 12(13):3942\u20133949","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10_CR53","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11523-010-0156-3","volume":"5","author":"G Tabatabai","year":"2010","unstructured":"Tabatabai G, Weller M, Nabors B et al (2010) Targeting integrins in malignant glioma. Target Oncol 5(3):175\u2013181","journal-title":"Target Oncol"},{"issue":"4","key":"10_CR54","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1586\/ern.11.188","volume":"12","author":"MC Chamberlain","year":"2012","unstructured":"Chamberlain MC, Cloughsey T, Reardon DA et al (2012) A novel treatment for glioblastoma: integrin inhibition. Expert Rev Neurother 12(4):421\u2013435","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"10_CR55","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1600-0404.1998.tb00609.x","volume":"97","author":"EL Lund","year":"1998","unstructured":"Lund EL, Spang-Thomsen M, Skovgaard-Poulsen H et al (1998) Tumor angiogenesis--a new therapeutic target in gliomas. Acta Neurol Scand 97(1):52\u201362","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10_CR56","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0090-3019(97)00218-8","volume":"49","author":"RL Jensen","year":"1998","unstructured":"Jensen RL (1998) Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 49(2):189\u2013195. discussion 196","journal-title":"Surg Neurol"},{"issue":"24","key":"10_CR57","first-page":"8890","volume":"63","author":"A Abdollahi","year":"2003","unstructured":"Abdollahi A, Lipson KE, Sckell A et al (2003) Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 63(24):8890\u20138898","journal-title":"Cancer Res"},{"issue":"8","key":"10_CR58","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1517\/13543784.17.8.1225","volume":"17","author":"DA Reardon","year":"2008","unstructured":"Reardon DA, Nabors LB, Stupp R et al (2008) Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17(8):1225\u20131235","journal-title":"Expert Opin Investig Drugs"},{"key":"10_CR59","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1756-9966-27-86","volume":"27","author":"L Oliveira-Ferrer","year":"2008","unstructured":"Oliveira-Ferrer L, Hauschild J, Fiedler W et al (2008) Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK\/src\/AKT pathway. J Exp Clin Cancer Res 27:86","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10_CR60","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.mcn.2008.08.005","volume":"39","author":"K Farber","year":"2008","unstructured":"Farber K, Synowitz M, Zahn G et al (2008) An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci 39(4):579\u2013585","journal-title":"Mol Cell Neurosci"},{"issue":"Pt3","key":"10_CR61","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1042\/bst0320434","volume":"32","author":"DA Calderwood","year":"2004","unstructured":"Calderwood DA (2004) Talin controls integrin activation. Biochem Soc Trans 32(Pt3):434\u2013437","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"10_CR62","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1535-7163.499.3.4","volume":"3","author":"S Swenson","year":"2004","unstructured":"Swenson S, Costa F, Minea R et al (2004) Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Mol Cancer Ther 3(4):499\u2013511","journal-title":"Mol Cancer Ther"},{"key":"10_CR63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/BF02789213","volume":"24-25","author":"P Riva","year":"1994","unstructured":"Riva P, Arista A, Sturiale C et al (1994) Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodies. Cell Biophys 24-25:37\u201343","journal-title":"Cell Biophys"},{"issue":"1","key":"10_CR64","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.2005.03.4082","volume":"24","author":"DA Reardon","year":"2006","unstructured":"Reardon DA, Akabani G, Coleman RE et al (2006) Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 24(1):115\u2013122","journal-title":"J Clin Oncol"},{"issue":"6","key":"10_CR65","first-page":"1042","volume":"46","author":"G Akabani","year":"2005","unstructured":"Akabani G, Reardon DA, Coleman RE et al (2005) Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 46(6):1042\u20131051","journal-title":"J Nucl Med"},{"issue":"2","key":"10_CR66","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1215\/15228517-2007-053","volume":"10","author":"DA Reardon","year":"2008","unstructured":"Reardon DA, Zalutsky MR, Akabani G et al (2008) A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro-Oncology 10(2):182\u2013189","journal-title":"Neuro-Oncology"},{"key":"10_CR67","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/194495a0","volume":"194","author":"WM Hunter","year":"1962","unstructured":"Hunter WM, Greenwood FC (1962) Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194:495\u2013496","journal-title":"Nature"},{"key":"10_CR68","unstructured":"American Cancer Society (2018) Cancer facts and figures 2018:21\u201323"},{"issue":"7","key":"10_CR69","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJM198908173210702","volume":"321","author":"ED Crawford","year":"1989","unstructured":"Crawford ED, Eisenberger MA, McLeod DG et al (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321(7):419\u2013424","journal-title":"N Engl J Med"},{"issue":"6","key":"10_CR70","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/cncr.23304","volume":"112","author":"RW Ross","year":"2008","unstructured":"Ross RW, Xie W, Regan MM et al (2008) Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 112(6):1247\u20131253","journal-title":"Cancer"},{"issue":"5","key":"10_CR71","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","volume":"66","author":"M Stanbrough","year":"2006","unstructured":"Stanbrough M, Bubley GJ, Ross K et al (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66(5):2815\u20132825","journal-title":"Cancer Res"},{"issue":"13","key":"10_CR72","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197","journal-title":"N Engl J Med"},{"issue":"2","key":"10_CR73","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138\u2013148","journal-title":"N Engl J Med"},{"issue":"2","key":"10_CR74","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152\u2013160","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10_CR75","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1538-7836.2011.04279.x","volume":"9","author":"RM Kini","year":"2011","unstructured":"Kini RM (2011) Toxins in thrombosis and haemostasis: potential beyond imagination. J Thromb Haemost 9(Suppl 1):195\u2013208","journal-title":"J Thromb Haemost"}],"container-title":["Methods in Molecular Biology","Snake and Spider Toxins"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-9845-6_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T10:47:43Z","timestamp":1721818063000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-9845-6_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,2]]},"ISBN":["9781493998449","9781493998456"],"references-count":75,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-9845-6_10","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,2]]},"assertion":[{"value":"2 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}